Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ: TSVT )

4.730 -0.280 (-5.59%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 211,505
Open 5.020
Bid (Size) 4.700 (2)
Ask (Size) 5.250 (1)
Prev. Close 5.010
Today's Range 4.685 - 5.040
52wk Range 1.535 - 6.400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
From 2seventy bio, Inc.
Via Business Wire
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The once-daily subcutaneous treatment showed significant bleeding reduction in... 
Via Benzinga

Performance

YTD
+15.37%
+15.37%
1 Month
-1.87%
-1.87%
3 Month
+12.09%
+12.09%
6 Month
+5.35%
+5.35%
1 Year
+116.97%
+116.97%

More News

Read More
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
Via Benzinga
Exposures Product Safety
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
From 2seventy bio
Via Business Wire
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
From 2seventy bio, Inc.
Via Business Wire
3 Hidden Stock Gems That Wall Street Is Overlooking
Via InvestorPlace
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
Via Benzinga
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024
Via InvestorPlace
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
From 2seventy bio, Inc.
Via Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Via Benzinga
Exposures Product Safety
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
Via Benzinga
Exposures Product Safety
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
From 2seventy bio, Inc.
Via Business Wire
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.